UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------
FORM 6-K
------------
REPORT OF FOREIGN ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
November 10, 2008
------------
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
NOVO ALLE
DK-2880, BAGSVAERD
DENMARK
(Address of principal executive offices)
------------
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F
Form 20-F [X] Form 40-F [ ]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b):82-_____________________
MISCELLANEOUS
MAJOR SHAREHOLDER NOTIFICATION
In accordance with Section 29 of the Securities Trading Act, Novo Nordisk
hereby reports that on 4 November 2008 Novo Nordisk received notification from
The Capital Group Companies Inc. that it pursuant to letter of application of 7
February 2008 to the Danish FSA regarding the exemption requirements for parent
companies under Executive Order 1225 section 12 and 14 no longer will report
interest in securities in Denmark on its own behalf. Instead, voting interest
and ownership in shares will be reported separately by Capital Research and
Management Company, Capital Group International Inc. or the mutual funds and
clients themselves, as appropriate. None of the individual entities have
shareholdings above the threshold of 5% of the issued share capital.
Further, The Capital Group Companies Inc. informed Novo Nordisk that the
filing is not being made to reflect an acquisition or disposition of shares, but
rather to reflect that the Capital Group Companies Inc. as a parent company is
exempted from the requirements to file aggregate ownership reports under
Executive Order 1225. Should the voting interests or ownership in shares held by
Capital Research and Management Company, Capital Group International Inc. or the
mutual funds and clients exceed a reporting threshold, such entity will file a
report separately in the future.
Novo Nordisk is a healthcare company and a world leader in diabetes care.
In addition, Novo Nordisk has a leading position within areas such as
haemostasis management, growth hormone therapy and hormone replacement therapy.
Novo Nordisk manufactures and markets pharmaceutical products and services that
make a significant difference to patients, the medical profession and society.
With headquarters in Denmark, Novo Nordisk employs approximately 26,550
employees in 80 countries, and markets its products in 179 countries. Novo
Nordisk's B shares are listed on the stock exchanges in Copenhagen and London.
Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For
more information, visit novonordisk.com.
FURTHER INFORMATION:
Media: Investors:
Elin K Hansen Mads Veggerby Lausten
Tel (direct): (+45) 4442 3450 Tel (direct): (+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com
Hans Rommer
Tel (direct): (+45) 4442 4765
hrmm@novonordisk.com
In North America:
Sean Clements Kasper Roseeuw Poulsen
Tel (direct): (+1) 609 514 8316 Tel (direct): (+45) 4442 4471
secl@novonordisk.com krop@novonordisk.com
Company Announcement no 73 / 2008
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf of the
undersigned, thereunto duly authorized.
Date: November 10, 2008 NOVO NORDISK A/S
---------------------------------------------------
Lars Rebien Sorensen,
President and Chief Executive Officer